Urgent call for timely, affordable access to new life-changing epilepsy treatments in Canada
January 10, 2024 07:00 ET
|
Canadian Epilepsy Alliance
Calgary, AB, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The Canadian Epilepsy Alliance, along with physicians, patients and their families are calling on provincial Health Ministers to address an unmet need...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 08, 2024 08:00 ET
|
Praxis Precision Medicines, Inc.
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion...
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
January 04, 2024 16:49 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public...
Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis
January 04, 2024 12:00 ET
|
CROSSJECT
Communiqué de presse Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis Crossject élargit ses activités d'accès au marché dans le cadre des...
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
January 04, 2024 12:00 ET
|
CROSSJECT
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ...
Brain Implants Market to Attain a Valuation of USD 8.8 billion by 2031: Transparency Market Research Study
January 04, 2024 04:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The brain implants market was valued at US$ 4.2 billion in 2022. A CAGR of 8.4% is forecast...
Crossject signe un accord de commercialisation pour ZEPIZURE® en Europe du Nord
December 22, 2023 01:30 ET
|
CROSSJECT
Crossject recevra jusqu'à 1 million d'euros en vue des approbations de mise sur le marché, plus un multiple des coûts de production lié à la marge brute L'accord, signé avec un partenaire stratégique...
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
December 22, 2023 01:30 ET
|
CROSSJECT
Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner, allows Crossject to benefit from strong...
Global Deep Brain Stimulation Market Size to Reach USD 4.27 Billion in 2032 | Emergen Research
December 12, 2023 07:31 ET
|
Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global Deep Brain Stimulation (DBS) market, valued at USD 1.70 Billion in 2022, is projected to witness a robust revenue Compound Annual Growth Rate...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 05, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...